Does TRT Cause Prostate Cancer? What 80 Years of Research Actually Shows
The fear of testosterone and prostate cancer traces back to a single experiment from 1941, and understanding why that experiment was misread explains almost everything about this topic.
A researcher named Huggins took men who had already been castrated as a treatment for advanced metastatic prostate cancer, then injected them with testosterone, and watched their cancer markers rise back up. The medical community drew what seemed like an obvious conclusion: removing testosterone helped, so adding testosterone must cause harm. That logic was so compelling that Huggins won the Nobel Prize for it.
The mistake was not the observation. The mistake was what they generalized from it.
Those men had been castrated, which means their testosterone had been driven down to near zero, and their prostate cells were starving for androgen stimulation. Giving them testosterone was like flooding a completely dry field. Of course everything responded. But that tells you nothing about what happens when you add testosterone to a man who already has normal levels.
The reason this matters comes down to something called receptor saturation, which is the point at which a tissue has absorbed all the hormonal signal it can handle and adding more stops making a difference. Every receptor has a ceiling.
Think of it like a sponge sitting in water. A dry sponge soaks up water fast and you can measure the difference easily. But a sponge that is already wet cannot absorb meaningfully more no matter how much water you pour. The prostate works the same way with testosterone.
Research published in 2009 mapped where that saturation point actually falls, and it lands at roughly 240 to 250 nanograms per deciliter. Below that threshold, changes in testosterone produce dramatic changes in prostate tissue response. Above it, additional testosterone has almost no effect because the androgen receptors are already fully occupied.
A healthy adult male typically sits somewhere between 400 and 900 nanograms per deciliter. A man on TRT is being brought up into that same normal range. Both of them are already well above the saturation threshold, which means the prostate is not responding to the additional signal the way it would in a castrated man.
That is the entire mechanism. That is why the 1941 experiment was never a valid model for TRT in hypogonadal men, let alone healthy ones.
Then the clinical data came in and confirmed it at scale.
The largest trial looked at 5,204 men randomized to either testosterone replacement or placebo and followed them for 33 months. Prostate cancer developed in 0.46 percent of the TRT group and 0.42 percent of the placebo group, a hazard ratio of 1.07 with a p-value of 0.87, which means there was essentially no difference and the margin that existed was not statistically meaningful.
A population study following 78,615 men for 18 years found that prostate cancer-specific mortality was actually lower in TRT users, with a hazard ratio of 0.52. That does not mean testosterone protects against prostate cancer death in some direct causal way, and the researchers appropriately noted limitations in interpreting that direction, but it does mean the data ran opposite to the fear.
A meta-analysis pulling together 28 randomized controlled trials measured PSA, which is something called prostate-specific antigen and serves as a blood marker for prostate stress or growth, and found it rose by 0.08 nanograms per milliliter in TRT users. That number is so small it sits within normal daily variation and was not statistically significant. The same analysis looked at urinary symptoms and found a change of literally zero.
The final piece of the argument is the one that is hardest to argue against.
A study examined 69,984 men who had already been treated for localized prostate cancer, and of those, 1,012 went on to receive testosterone therapy afterward. Researchers tracked recurrence rates and death rates, and found no increase in either. If testosterone cannot cause existing, confirmed prostate cancer to recur or progress in men who already have it, the argument that it causes prostate cancer in healthy men becomes very difficult to sustain.
None of this means you ignore the prostate entirely when starting TRT. The monitoring exists because the prostate does respond to testosterone in meaningful ways at the lower end of the range, and because a pre-existing cancer that was subclinical before TRT may become detectable after, which looks like TRT caused it but is actually just detection timing.
Get a baseline PSA before you start. Check it again at three to six months and then annually after that. If PSA rises more than 1.4 nanograms per milliliter above your individual baseline, that is the threshold the Endocrine Society guidelines flag as a reason to refer to a urologist for further evaluation. Not a reason to panic, a reason to look closer.
The fear of TRT and prostate cancer has been widespread and durable, and it persisted because the original 1941 finding felt intuitive and the person who produced it won the highest scientific prize available. But intuition built on a dry-sponge model was always going to fail when applied to a wet one.
The science that replaced that model has had decades and hundreds of thousands of patients to make its case, and it keeps making the same case every time the data comes in.
References
- Huggins CV, Hodges CV. 1941. "Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate." Cancer Research. 14:293-297. Finding: Castration reduced acid phosphatase in men with metastatic prostate cancer; testosterone injection into castrated men raised it back. Source
- Morgentaler A, Traish AM. 2009. "Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth." European Urology. 552:310-320. Finding: Prostate androgen receptors saturate at approximately 240-250 ng/dL; above this threshold, additional testosterone produces minimal prostate effect. Source
- Bhasin S, Travison TG, Pencina KM, et al. 2023. "Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial." JAMA Network Open. 612:e2348692. Finding: 5,204 men, 33 months. Prostate cancer: 0.46% TRT vs 0.42% placebo HR 1.07, p=0.87. No significant difference. Source
- Siltari A, Murtola TJ, Kausz J, et al. 2023. "Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men." Acta Oncologica. 6211-12:1755-1762. Finding: 78,615 men, 18-year follow-up. Prostate cancer-specific mortality LOWER in TRT users HR 0.52. Source
- Xu Z, Chen X, Zhou H, et al. 2024. "An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate." Frontiers in Endocrinology. 15:1335146. Finding: 28 RCTs. PSA change: 0.08 ng/mL not significant. IPSS change: 0.00 literally zero difference. Source
- Sarkar RR, Patel SH, Parsons JK, et al. 2021. "Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease." Prostate Cancer and Prostatic Diseases. 24:739-746. Finding: 69,984 men with treated prostate cancer, 1,012 received TRT. No increase in recurrence or death. Source
- Bhasin S, Brito JP, Cunningham GR, et al. 2018. "Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline." JCEM. 1035:1715-1744. Finding: Refer to urology if PSA rises >1.4 ng/mL above baseline. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.